Relmada Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 98.79 million compared to USD 157.04 million a year ago. Basic loss per share from continuing operations was USD 3.28 compared to USD 5.3 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.83 USD | +3.51% | -4.25% | -7.49% |
Mar. 19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
Mar. 19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.49% | 116M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023